Standout Papers

Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberou... 2012 2026 2016 2021 567
  1. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial (2012)
    David Neal Franz, Е. Д. Белоусова et al. The Lancet

Immediate Impact

1 from Science/Nature 57 standout
Sub-graph 1 of 20

Citing Papers

The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
2023 Standout
Adult epilepsy
2023 Standout
2 intermediate papers

Works of James Ford being referenced

Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial
2012 Standout

Author Peers

Author Last Decade Papers Cites
James Ford 206 1 202 375 7 605
Helene Cauwel 180 183 375 4 588
Maxwell Mays 210 1 173 411 6 657
C. Welsh 162 80 256 7 624
Tara M. Lichtenberg 340 3 148 240 7 619
Ida Enquist 137 65 279 307 13 649
Lucia Longa 187 1 163 447 10 585
Yvonne Chekaluk 285 180 408 11 665
Michaela Hanneder 453 4 125 113 10 604
Danyi Zhou 190 8 283 114 13 560
Magdalena E. Tyburczy 230 157 412 11 586

All Works

Loading papers...

Rankless by CCL
2026